BioPharma Dive 2026-02-24 Novo, searching for a spark, spotlights new data for three-pronged obesity drug
BioPharma Dive 2026-02-23 Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
BioPharma Dive 2026-02-19 Altesa, run by former Trump official, raises $75M for well-traveled lung drug
BioPharma Dive 2026-02-19 FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
BioPharma Dive 2026-02-18 FDA accepts BMS protein degrader for review; Disc rare disease drug rejected